<DOC>
	<DOCNO>NCT00642018</DOCNO>
	<brief_summary>The primary purpose study determine whether LY2181308 combination docetaxel safe effective treatment hormone refractory prostate cancer patient .</brief_summary>
	<brief_title>A Study Experimental Chemotherapy Combination Treat Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate metastatic and/or unresectable Hormone refractory prostate cancer define progressive base document 2 increase PSA value previous reference value . ECOG status 02 Adequate hematological function , liver renal function Known hypersensitivity docetaxel taxane therapy Documented central nervous system leptomeningeal metastasis time study entry Had prior treatment chemotherapy , bone seek radionucleides past 6 week prior enrollment , radiotherapy involve 25 % marrow produce area . Evidence painful and/or destructive bone metastases radiation therapy , biophosphonates boneseeking radionucleides necessary . Have receive treatment last 30 day drug receive regulatory approval indication time study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
</DOC>